|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0019134,
umls-concept:C0027051,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0035124,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0205178,
umls-concept:C0206460,
umls-concept:C0247025,
umls-concept:C0348016,
umls-concept:C0443315,
umls-concept:C0702240,
umls-concept:C1696465
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2003-10-17
|
|
pubmed:abstractText |
The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0735-1097
|
|
pubmed:author |
pubmed-author:BigonziFrederiqueF,
pubmed-author:CohenMarcM,
pubmed-author:DanchinNicolasN,
pubmed-author:GensiniGian FrancoGF,
pubmed-author:GurfinkelEnrique PEP,
pubmed-author:HecquetCaroleC,
pubmed-author:HuberKurtK,
pubmed-author:Krzeminska-PakulaMariaM,
pubmed-author:MaritzFransF,
pubmed-author:SantopintoJoseJ,
pubmed-author:TETAMI Investigators,
pubmed-author:TimermanAriA,
pubmed-author:VittoriLucL,
pubmed-author:WhiteHarvey DHD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1348-56
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14563573-Administration, Oral,
pubmed-meshheading:14563573-Aspirin,
pubmed-meshheading:14563573-Double-Blind Method,
pubmed-meshheading:14563573-Drug Therapy, Combination,
pubmed-meshheading:14563573-Electrocardiography,
pubmed-meshheading:14563573-Enoxaparin,
pubmed-meshheading:14563573-Female,
pubmed-meshheading:14563573-Fibrinolytic Agents,
pubmed-meshheading:14563573-Heparin,
pubmed-meshheading:14563573-Humans,
pubmed-meshheading:14563573-Incidence,
pubmed-meshheading:14563573-Injections, Intravenous,
pubmed-meshheading:14563573-Injections, Subcutaneous,
pubmed-meshheading:14563573-Male,
pubmed-meshheading:14563573-Middle Aged,
pubmed-meshheading:14563573-Myocardial Infarction,
pubmed-meshheading:14563573-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:14563573-Recurrence,
pubmed-meshheading:14563573-Time Factors,
pubmed-meshheading:14563573-Tyrosine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
|
|
pubmed:affiliation |
Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA. marcohen@sbhcs.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
